dm+d

Unassigned

New Medicines

Chronic graft versus host disease (GvHD)

Information

New molecular entity
Incyte
Incyte

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Janus-associated kinase 1 (JAK1) inhibitor
The number of allogeneic bone marrow and stem cell transplants is increasing worldwide. Graft-versus-host disease (GvHD) is a serious complication of this type of transplant. The incidence of acute GvHD varies widely, ranging from 10-80% depending on risk factors [1].
Chronic graft versus host disease (GvHD)
Oral